The Superiority of AVAPS Mode of Non-invasive Ventilation in Combination with HFNC Over HFNC Alone in Patients with Chronic Obstructive Pulmonary Disease Complicated by Respiratory Failure

Abstract

Objective

This paper was designed to investigate the clinical efficacy of combining the Average Volume Assured Pressure Support (AVAPS) mode of non-invasive ventilation (NIV) with high-flow nasal cannula oxygenation (HFNC) oxygen therapy in managing chronic obstructive pulmonary disease (COPD) patients complicated by respiratory failure.

Methods

Ninety-six patients with COPD and respiratory failure were enrolled and classified into a control group and an observation group. Both groups received conventional treatment. The control group was treated with AVAPS-mode NIV, while the observation group received additional HFNC. Clinical outcomes, adverse reactions, clinical indicators, blood gas parameters, serum inflammatory markers, and pulmonary function indicators were compared between the two groups.

Results

The observation group had a significantly higher overall clinical response rate (93.75% vs 75.00%, P < 0.05), shorter ICU stays and mechanical ventilation times, lower respiratory rates, higher PaO₂, SaO₂, FEV₁, FVC, and FEV₁/FVC values, and lower PaCO₂, IL-6, IL-8, TNF-α, and sTREM-1 levels than the control group (all P < 0.05). Heart rate did not differ significantly between the two groups (P > 0.05). The adverse reaction rate was significantly lower in the observation group relative to the control group (4.17% vs 18.75%, P < 0.05).

Conclusion

This combined approach demonstrates superior efficacy in treating COPD patients with respiratory failure, improving arterial blood gas and pulmonary function, reducing inflammatory responses, and exhibiting a high safety profile.